Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails ... - Morningstar

Retrieved on: 2024-01-05 17:19:22

Tags for this article:

Click the tags to see associated articles and topics

Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails ... - Morningstar. View article details on hiswai:

Excerpt

Theravance Biopharma Inc.'s stock (TBPH) tumbled 21% early Friday,ter the biotech said a Phase 4 trial of its Yupelri treatment for patients with ...

Article found on: www.morningstar.com